The success of microneedle-mediated vaccine delivery into skin

Simple item page
dc.contributor.authorMarshall, Sarah
dc.contributor.authorSahm, Laura J.
dc.contributor.authorMoore, Anne C.
dc.date.accessioned2019-09-17T08:58:30Z
dc.date.available2019-09-17T08:58:30Z
dc.date.issued2016-11-01
dc.date.updated2019-09-17T08:50:11Z
dc.description.abstractMicroneedles (MNs) are designed to specifically target the outermost, skin barrier layer, the stratum corneum, creating transient pathways for minimally invasive transcutaneous delivery. It is reported that MNs can facilitate delivery without stimulating the pain receptors or damaging blood vessels that lie beneath, thus being perceived as painless and associated with reduced bleeding. This immunocompetence of the skin, coupled with its ease of access, makes this organ an attractive vaccination site. The purpose of this review was to collate primary scientific literature pertaining to MN-mediated in vivo vaccination programmes. A total of 62 original research articles are presented, compiling vaccination strategies in 6 different models (mouse, rat, guinea pig, rabbit, pig, macaque and human). Vaccines tested span a wide range of viral, bacterial and protozoan pathogens and includes 7 of the 13 vaccine-preventable diseases, as defined by the WHO. This review highlights the paucity of available clinical trial data. MN-delivered vaccines have demonstrated safety and immunogenicity in pre-clinical models and boast desirable attributes such as painless administration, thermostability, dose-sparing capacity and the potential for self-administration. These advantages should contribute to enhanced global vaccine access.en
dc.description.statusPeer revieweden
dc.description.versionAccepted Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.citationMarshall, S., Sahm, L. J. and Moore, A. C. (2016) 'The success of microneedle-mediated vaccine delivery into skin', Human Vaccines and Immunotherapeutics, 12(11), pp. 2975-2983. doi: 10.1080/21645515.2016.1171440en
dc.identifier.doi10.1080/21645515.2016.1171440en
dc.identifier.eissn2164-554X
dc.identifier.endpage2983en
dc.identifier.issn2164-5515
dc.identifier.issued11en
dc.identifier.journaltitleHuman Vaccines and Immunotherapeuticsen
dc.identifier.startpage2975en
dc.identifier.urihttps://hdl.handle.net/10468/8535
dc.identifier.volume12en
dc.language.isoenen
dc.publisherTaylor & Francis Groupen
dc.rights© 2016, Taylor & Francis Group. This is an Accepted Manuscript of an article published by Taylor & Francis in Human Vaccines and Immunotherapeutics on 1 November 2016, available online: https://doi.org/10.1080/21645515.2016.1171440en
dc.subjectMicroneedleen
dc.subjectSkinen
dc.subjectVaccineen
dc.titleThe success of microneedle-mediated vaccine delivery into skinen
dc.typeArticle (peer-reviewed)en
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
The_success_of_microneedle-mediated_vaccine_delivery_into_skin_(final)_(002).pdf
Size:
547.49 KB
Format:
Adobe Portable Document Format
Description:
Accepted Version
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Pharmacy - Journal Articles
Pharmacology and Therapeutics - Journal Articles